- Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A)
March 06 2009 - 1:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant
o
Filed by a Party other than the Registrant
þ
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
o
Definitive Additional Materials
þ
Soliciting Material Pursuant to §240.14a-12
(Name of Registrant as Specified In Its Charter)
Astellas Pharma, Inc., Astellas US Holding, Inc.,
Sturgeon Acquisition, Inc.
(Names of Persons Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ
|
|
No fee required.
|
|
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
|
|
|
2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
|
|
|
3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (set
forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
|
|
|
|
4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
|
|
|
5)
|
|
Total fee paid:
|
|
|
|
|
|
o
|
|
Fee paid previously with preliminary materials.
|
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the form or schedule and the
date of its filing:
|
|
1)
|
|
Amount Previously Paid:
|
|
|
|
|
|
|
|
2)
|
|
Form, Schedule or Registration Statement No:
|
|
|
|
|
|
|
|
3)
|
|
Filing Party:
|
|
|
|
|
|
|
|
4)
|
|
Date Filed:
|
|
|
|
|
|
The following press release was issued by Astellas Pharma Inc. on Friday, March 6, 2009:
|
|
|
Media Contacts
|
|
Investor Contact
|
Sard Verbinnen & Co
|
|
Georgeson Inc.
|
Jim Barron (212) 687-8080
|
|
Tom Gardiner (212) 440-9872
|
Andrew Cole (415) 618-8750
|
|
|
ASTELLAS TO NOMINATE TWO DIRECTORS AND SUBMIT PROPOSAL TO
REMOVE REMAINING FOUR DIRECTORS OF CV THERAPEUTICS
Tokyo, Japan, March 6, 2009
Astellas Pharma Inc. today announced that its wholly owned
subsidiary, Astellas US Holding, Inc., will nominate two directors for election to the Board of
Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) and submit a stockholder proposal to remove the
remaining four directors at the 2009 Annual Meeting.
The election of the two Astellas nominees requires a plurality of the stockholder votes cast.
Under CV Therapeutics certificate of incorporation, the remaining directors can be removed without
cause by holders of 2/3 of the outstanding shares of CV Therapeutics.
Astellas has identified two highly qualified independent nominees to replace CV Therapeutics
Chairman and Chief Executive Officer Louis G. Lange, M.D., Ph.D. and Director Thomas E. Shenk, Ph.D., the
two CV Therapeutics directors whose terms of office expire at the 2009 Annual Meeting.
Astellas stated, While we continue to prefer a negotiated agreement with CV Therapeutics, the
refusal of the Board to engage us has left us no alternative but to take our offer directly to the
companys stockholders and also to ask them to elect a Board that is willing to consider
opportunities to maximize value for all CV Therapeutics shareholders.
Astellas is currently reviewing the recent changes made by CV Therapeutics to its bylaws, which
require, among other things, that each nominee complete a questionnaire and provide a
representation and agreement in connection with their nomination. Upon completion of this process,
Astellas will disclose its nominees.
Astellas intends to provide formal notice of its nominees and stockholder proposal to CV
Therapeutics prior to the deadline for submitting proposals for the 2009 Annual Meeting, as
announced in the proxy statement for its 2008 Annual Meeting. CV
Therapeutics has yet to announce a
date for the 2009 Annual Meeting or a record date for the meeting.
The 2008 Annual Meeting was held on May 20, 2008, and the record
date was March 20, 2008.
On February 27, 2009, Astellas commenced a $16.00 per share cash tender offer, which represents a
41% premium to CV Therapeutics closing share price on January 26, 2009, the day prior to the
public disclosure of Astellas proposal, and a 69% premium to CV Therapeutics 60-day average
closing price ending January 26th. The tender offer is not conditioned on financing and represents
a total equity value of approximately $1.1 billion. The offer and withdrawal rights are scheduled
to expire at 12:01 a.m., New York City time on March 27, 2009, unless the offer is extended.
The complete Offer to Purchase, Letter of Transmittal and other offering documents have been filed
with the U.S. Securities and Exchange Commission. CV Therapeutics stockholders may obtain copies
of all of the offering documents, including the Offer to Purchase, free of charge at the SECs
website (
www.sec.gov
) or by directing a request to Georgeson Inc., the Information Agent for the
offer, at (212) 440-9800. Additional information about the transaction, including the offering
documents, is also available at
www.cvtxvalue.com
.
On February 27, 2009, Astellas also filed a complaint in the Delaware Court of Chancery seeking,
among other things, to invalidate recent amendments to CV Therapeutics poison pill stockholder
rights plan. A copy of the complaint may be found at
www.cvtxvalue.com
.
About Astellas
Astellas Pharma Inc., with global headquarters in Tokyo and US headquarters in Deerfield, Illinois,
is a pharmaceutical company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products. The organization is committed to
becoming a global pharmaceutical company by combining outstanding R&D and marketing capabilities
and continuing to grow in the world pharmaceutical market.
Astellas was formed by the historical merger of Japans third and fifth largest pharmaceutical
companies Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Today, Astellas is one of
the largest pharmaceutical companies in Japan with a market capitalization of approximately $17.7
billion as of January 26, 2009, and, for the fiscal year ended March 31, 2008, net income of
approximately $1.8 billion.
The company has approximately 14,000 employees worldwide. This includes 7,500 in Japan, 3,300 in
Europe, 2,200 in North America and 1,000 in Asia. Some of Astellas core products in the US are:
Lexiscan
®
(regadenoson) and Adenoscan
®
(adenosine injection), pharmacologic
stress agents indicated for radionuclide myocardial perfusion imaging/scintigraphy (MPI/S) in
patients unable to undergo adequate exercise stress; Prograf
®
(tacrolimus), an
immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving organ
transplants; and VESIcare
®
(solifenacin succinate), indicated for the treatment of
overactive bladder with symptoms of urgency, frequency, and urge incontinence.
Astellas is publicly traded on the Tokyo Stock Exchange. For more information about Astellas
Pharma Inc., please visit
www.astellas.com
. For more information about Astellas Pharma US, Inc.,
please visit
http://www.us.astellas.com/
.
Additional Information
This announcement is for informational purposes only and does not constitute an offer to purchase
or a solicitation of an offer to sell CV Therapeutics, Inc. common stock. The tender offer is
being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase,
Letter of Transmittal and other related tender offer materials) filed by Astellas with the
Securities and Exchange Commission (SEC) on February 27, 2009. These materials, as they may be
amended from time to time, contain important information, including the terms and conditions of the
offer, that should be read carefully before any decision is made with respect to the tender offer.
Investors and security holders may obtain a free copy of these materials and other documents filed
by Astellas with the SEC at the website maintained by the SEC at www.sec.gov. The Offer to
Purchase, Letter of Transmittal and other related tender offer materials may also be obtained for
free by contacting the information agent for the tender offer, Georgeson Inc. at (212) 440-9800.
Each of Astellas and Astellas US Holding, Inc. and certain of their directors and executive
officers, as well as the individuals nominated by Astellas US Holding, Inc. for election to CV
Therapeutics, Inc.s board of directors, may be deemed to be participants in a solicitation of
proxies in connection with CV Therapeutics, Inc.s 2009 Annual Meeting of Stockholders or at any
adjournment or postponement thereof. Information regarding Astellas and Astellas US Holding,
Inc.s directors and executive officers is available in the Schedule TO and other documents filed
by Astellas with the SEC as described above, and further information will be available in Astellas
proxy statement to be filed with the SEC in connection with the solicitation of proxies in due
course. As of the date of this filing, Astellas US Holding, Inc. is the record holder of 54,270
shares of common stock of CV Therapeutics, Inc. and Astellas is deemed to be the beneficial owner
of 54,270 shares of common stock of CV Therapeutics, Inc. Stockholders of CV Therapeutics, Inc.
are advised to read Astellas proxy statement when it becomes available, because it will contain
important information. Stockholders of CV Therapeutics, Inc. and other interested parties may
obtain, free of charge, copies of the proxy statement (when available), and any other documents
filed by Astellas with the SEC in connection with the proxy solicitation, at the SECs website as
described above. The proxy statement (when available) and these other documents may also be
obtained free of charge by contacting Georgeson Inc. at the number listed above.
No assurance can be given that the proposed transactions described herein will be consummated by
Astellas, or completed on the terms proposed or any particular schedule, that the proposed
transactions will not incur delays in obtaining the regulatory, board or stockholder approvals
required for such transactions, or that Astellas will realize the anticipated benefits of any
proposed transactions.
Any information regarding CV Therapeutics contained herein has been taken from, or is based upon,
publicly available information. Although Astellas does not have any information that would
indicate that any information contained herein is inaccurate or incomplete, Astellas does not
undertake any responsibility for the accuracy or completeness of such information.
Astellas does not undertake, and specifically disclaims, any obligation or responsibility to update
or amend any of the information above.
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024